Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving blood clotting factor
Patent
1997-09-08
2000-09-12
Gitomer, Ralph
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving blood clotting factor
435 696, C12Q 156
Patent
active
061176486
ABSTRACT:
Blood coagulation factor XII (FXII) is activated using a receptor for globular heads of the complement component Clq. The receptor (gC1qr) is a protein and provides a more faithful in vitro reproduction of the actual FX-II-activating reaction which occurs in living organisms. The protein receptor, gClqR may be obtained in at least substantially pure or isolated form by recombinant genetic engineering techniques or by isolation from animal cell membranes to which the complement component Clq binds. The receptor may be separated, purified, or isolated from cell membranes. The activation of the blood coagulation factor XII may be conducted in: 1) an animal plasma, 2) a reconstituted plasma kallikrein-kinin system, or 3) an at least substantially pure blood coagulation factor XII. The activation with the receptor is preferably conducted in the presence of zinc ions. FXII may be subjected to an activation reaction with the isolated or at least substantially purified receptor for globular heads of Clq in the presence of a pharmaceutical to evaluate or measure the pharmaceutical's inhibiting or promoting action towards the plasma kallikrein-kinin system, blood coagulation system, fibrinolysis system, renin-angiotensin system, complement system, or arachidonate cascade. The drug screening may include evaluation of a compound's utility as an antiinflammatory agent, an antiallergic agent, or an analgesic.
REFERENCES:
patent: 4985354 (1991-01-01), Toyomaki et al.
patent: 5560935 (1996-10-01), Konishi et al.
patent: 5599683 (1997-02-01), Nishikawa et al.
patent: 5648228 (1997-07-01), Nishikawa et al.
Ghebrehiwet B., Identification of Functional Domans on GC1Q-R, a Cell Surface Protein That Binds to the Globular Heads of C1Q, Using Monoclonal Antibodies and Synthetic Peptides, Hybridoma 15(5):333-342, May 1996.
Kusumam J., Identification of the Zinc Dependent Endothelial Cell Binding Protein for High Molecular Weight Kininogen and F XII, Proc Natl Acad Sci USA 93:8552-8557, Aug. 1996.
Kaplan A., Binding of Activation of Kinin Forming Proteins on Vascular Endothelial Cells, Immunopharmacology 36:201-207, 1997.
Herwald et al., "Isolation and Characterization of the Kininogen-binding Protein p33 from Endothelial Cells", J. Biological. Chem. vol. 271, No. 22, 1996, pp. 13040-13047 May 31, 1966.
Ghebrehiwet et al., "Isolation cDNA Cloning, and Overexpression of a 33-kD Cell surface Glycoprotein that Binds to the Globular "Heads" of Clq", J. Exp. Medicine, vol. 179, No. 6, 1994, pp. 1809-1821. Jun. 1994.
Kaplan Allen P.
Shibayama Yoji
Gitomer Ralph
Nippon Zoki Pharmaceutical Co. Ltd.
LandOfFree
Method for the activation of blood coagulation factor XII does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the activation of blood coagulation factor XII, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the activation of blood coagulation factor XII will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-94570